Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

Liam James 2025 Nov 11, 00:00

Wall Street Optimists: Strong Earnings to Fuel US Equity Growth in 2026

Liam James 2025 Nov 11, 00:00

Oil Price Stability: A Risk Assessment and Future Outlook

Frances Wang 2025 Nov 09, 16:00

Growth tech stocks to watch 2026: Nvidia (NVDA) stock, Netflix (NFLX)

Frances Wang 2025 Nov 09, 16:00

Crypto trading basics: What is Ethereum? Does ETH have any future?

Frances Wang 2025 Nov 09, 16:00

A guide to crypto ETFs: Bitcoin ETF vs. Ethereum ETF, what’s the difference?

Ava Grace 2025 Nov 08, 00:00

AI Funding Concerns Trigger Tech Stock Sell-Off

Sophia Claire 2025 Nov 08, 00:00

Gold Price Outlook: Currency Devaluation Trade Still Alive

Frances Wang 2025 Nov 06, 16:00

Gold and silver prices are up: what's happening to Gold (XAU/USD) and XAG?

Frances Wang 2025 Nov 06, 16:00

Nvidia Competitors Analysis (2026), NVDA Stock: AMD, Intel, Qualcomm, AVGO

Frances Wang 2025 Nov 05, 16:00

Crypto market update: Ethereum price drops, Bitcoin price falls below $104K

Latest news

Show more
Ava Grace 2025 Nov 11, 00:10

Crypto Revenue Revolution: How Builder Codes are Earning Developers Millions

Emma Rose 2025 Nov 11, 00:00

Nord Stream Probe: Ukraine's Complications and German Support at Stake

Emma Rose 2025 Nov 11, 00:00

FX Market Calms Post-Trump Shockwave: Return to Traditional Drivers

Liam James 2025 Nov 11, 00:00

Gold & Silver Surge as Fed Rate Cut Expectations Mount

Noah Lee 2025 Nov 11, 00:00

BOJ October Meeting Minutes Signal Possible Rate Hike

Noah Lee 2025 Nov 11, 00:00

Investors Await Buffett's Letter Amid Berkshire's Strong Market Performance

Liam James 2025 Nov 11, 00:00

Syrian President's White House Visit: A Remarkable Turnaround

Ava Grace 2025 Nov 10, 23:30

Propanc Biopharma Secures $100M for Crypto Treasury, Eyes Cancer Therapy Trials

Info

Spread

0.7498

Spread (%)

0.7169 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Tuesday

14:31 - 20:59

Monday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

24800575488

Shares Outstanding

240455450

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-1.64

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Nov 09, 16:00

Commodity trading: What is platinum, is it better to buy gold or platinum?

Ghko B 2025 Nov 09, 16:00

Gold price forecast 2025/2026/2027: How to analyze gold prices (XAU/USD)?

Ghko B 2025 Nov 06, 16:00

How to start cryptocurrency trading: how to trade BTC Price (BTC/USD) CFDs?

Trustpilot